Transferrin receptor 1

Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery

Retrieved on: 
Thursday, January 4, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Liver, Traffic barrier, Broad Institute, Transferrin receptor 1, DSM-IV codes, BBB, Vector, MIT, Astrocyte, Brain, Transferrin, Endothelium, Gene expression, AAV, Engineering, CNS, Harvard University, Transport, Central nervous system, Iron, Patient, Psychiatry, Gene therapy, Neuron, Vaccine

Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).

Key Points: 
  • Apertura Gene Therapy , a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1).
  • This transportation mechanism mediates crossing of the blood-brain barrier (BBB) to enable gene therapy delivery throughout the central nervous system (CNS).
  • “Our TfR1 capsids, with their well-characterized mechanism of action, offer the unique advantage of significantly reducing human translation risk – a major historical challenge of engineering novel AAV capsids.
  • Apertura is currently advancing two programs utilizing its TfR1 capsids for undisclosed neurologic conditions and is leveraging its platform technologies to engineer novel payloads to regulate genetic expression and develop additional AAV capsids targeting specific human receptors.

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Retrieved on: 
Tuesday, July 19, 2022
NASH, Research, RNA, OTCQB, Cancer, Patient, Central nervous system, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Large-cell lung carcinoma, TFR1, Security (finance), Transferrin, Paclitaxel, U.S. Securities and Exchange Commission, Fatty liver disease, Safety, Sirna, Therapy, Type 1 diabetes, FAP, GLOBE, Private Securities Litigation Reform Act, Food, Transferrin receptor 1, Forward-looking statement, ATRX, Risk, Psychiatry, Melior Discovery, Drug development, Company, Hypercalcaemia, Lung cancer, Rouge, Breast, Malignancy, Gallium, FDA, CD71, PGT, Movement, Pharmaceutical industry

PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1.

Key Points: 
  • PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1.
  • Sb-paclitaxel is approved for breast, ovarian, and lung cancer and Kaposis Sarcoma, while nab-paclitaxel is approved for breast, pancreatic, and non-small cell lung cancer.
  • Gallium nitrate (brand name GANITE) is FDA-approved for hypercalcemia of malignancy, a common finding in patients with advanced stage cancer.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 5, 2021
Science, Toxicity, Drug discovery, SAN, Antibody, Neoplasm, Transferrin receptor 1, Safety, LinkedIn, Â, Clinical trial, Amgen, National, ALCAM, Twitter, Bristol Myers Squibb, Food and Drug Administration, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Interest, Therapy, Risk, CD137, United, IND, Tumor microenvironment, Clinical Cancer Research, Food, GLOBE, AbbVie, Investment, Webcast, Breast cancer, Journal, ADC, Program, Patient, COVID-19, Ipilimumab, Triple-negative breast cancer, B-cell lymphoma, Nasdaq, Immunotherapy, Biotechnology, Head, National academy, Nivolumab, International, Pharmaceutical industry, Tutoring, Medical imaging, Vaccine

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today reported second quarter 2021 financial results and provided a business update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today reported second quarter 2021 financial results and provided a business update.
  • In the second quarter of 2021, we continued to advance our broad pipeline of Probody therapeutics across multiple modalities and cancer types.
  • Initial data from this study is anticipated in the fourth quarter of 2021.
  • CytomX will continue to discuss the program with Amgen and is working toward the filing of an IND in late 2021.

CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health care, Biotechnology, Health sciences, Immunology, Antineoplastic drugs, Bristol-Myers Squibb, Ipilimumab, Antibody-drug conjugate, AbbVie, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Key Points: 
  • Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy.
  • We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029).

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Clinical medicine, Medicine, Immunology, AbbVie, Monoclonal antibody therapy, Monomethyl auristatin E, Transferrin receptor 1, Antibody-drug conjugate

In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71 conjugated to the cytotoxic payload MMAE.

Key Points: 
  • In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71 conjugated to the cytotoxic payload MMAE.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • The CytomX clinical stage pipeline includes first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029).
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

Retrieved on: 
Monday, March 30, 2020
Iron metabolism, Transferrin receptor 1, AbbVie Inc., Companies, Transferrin receptor, Transferrin, Chemistry, Illinois

In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71.

Key Points: 
  • In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71.
  • CD71, also known as the transferrin receptor 1 (TfR1), is a cell surface protein essential for iron uptake in dividing cells.
  • Under the agreement, CytomX is responsible for clinical development up to initial clinical proof of concept.
  • CytomX and AbbVie are finalizing plans for the advancement of CX-2029 to Phase 2 expansion cohorts in select tumor types.